Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay (Q42211136)

18 October 2017

title

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay (English)

1 reference

18 October 2017

0 references

1 reference

Françoise Brun-Vézinet

object named as

Françoise Brun-Vézinet

1 reference

18 October 2017

Gilles Peytavin

1 reference

18 October 2017

Diane Descamps

1 reference

18 October 2017

Charlotte Charpentier

object named as

Charlotte Charpentier

1 reference

18 October 2017

Yazdan Yazdanpanah

1 reference

18 October 2017

Roland Landman

1 reference

18 October 2017

Benoit Visseaux

1 reference

18 October 2017

Patrick Yeni

1 reference

18 October 2017

Marion Choquet

1 reference

18 October 2017

Véronique Joly

1 reference

18 October 2017

Marion Caseris

1 reference

18 October 2017

language of work or name

English

0 references

publication date

19 June 2014

1 reference

Journal of Antimicrobial Chemotherapy

18 October 2017

published in

1 reference

18 October 2017

1 reference

18 October 2017

1 reference

18 October 2017

page(s)

2819-2825

1 reference

Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Detection of HIV-1 at between 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is associated with higher pretherapy viral load and less time on antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU211

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU211

1 reference

18 October 2017

1 reference